GlassScriptPhysician profile
Taylor R Stone
NPI 1750788105
$8,363.33
in general payments reported to CMS, 2019-2025
30 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,309 · 2022: $1,337 · 2023: $1,559 · 2024: $1,895 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,204 · Education: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,203.50 |
| Education | $512.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $850.16 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $835.29 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $557.43 | 2021-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $535.34 | 2023-2025 | Opzelura |
| Genzyme Corporation | $468.91 | 2021-2025 | |
| Leo Pharma INC. | $463.36 | 2021-2025 | Adbry, Spevigo |
| Amgen INC. | $420.41 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $409.46 | 2021-2025 | |
| Pfizer INC. | $372.87 | 2021-2025 | |
| Galderma Laboratories, L.P. | $346.73 | 2021-2025 | Nemluvio, Twyneo, Oracea |
| Arcutis Biotherapeutics, INC. | $300.11 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $169.78 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $141.15 | 2021-2025 | |
| Biofrontera INC. | $121.38 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $107.69 | 2021-2025 | Bimzelx |
| Botanix Sb INC | $91.44 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $61.93 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.48 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.34 | 2021-2023 | Jublia |
| E.R. Squibb & Sons, L.L.C. | $45.05 | 2023 | Sotyktu |
| Lilly USA, LLC | $36.23 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Organon LLC | $32.54 | 2024-2025 | Vtama |
| Revance Therapeutics, INC. | $32.49 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $28.47 | 2023-2024 | |
| Lnhc, INC | $26.36 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $18.11 | 2023 | Vyjuvek |
| Medtronic, INC. | $17.11 | 2023 | Venaseal |
| Epi Health, LLC | $15.39 | 2021 | |
| Almirall LLC | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.